Advanced Parkinson's DiseasePhase 3NCT02549092
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
A Phase 3 study testing Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel and Nasojejunal (NJ) tube in people with Advanced Parkinson's Disease, run by AbbVie at 38 sites in 9 countries.
Trial summary
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD. Read more about this study
- Who is it for?
- Ages 30 years and older
- Conditions the study is for
- Advanced Parkinson's Disease
- What is being tested?
- Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel and Nasojejunal (NJ) tube
- Type of treatment
- Pill or oral medicine, Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 89 participants
- Where
- 38 sitesin 9 countries
- Study dates
- 26 Oct 2015to 18 Nov 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant(s) must have a diagnosis of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria.
- Participant(s) demonstrates persistent motor fluctuations in spite of individually optimized treatment.
- The participant's Parkinson's disease is levodopa-responsive.
- Participant(s) has had optimized treatment with available anti-PD medication and their motor symptoms are judged inadequately controlled on this optimized treatment. Optimized treatment is defined as the maximum therapeutic effect obtained with pharmacological antiparkinsonian therapies when no further improvement is expected regardless of any additional manipulations of levodopa and/or other antiparkinsonian medication. This will be based on the Investigator's clinical judgment.
- Male or female participant(s) must be at least 30 years of age.
- Minimum Parkinson's Disease Sleep Scale 2 (PDSS-2) total score of 18 at Baseline assessment.
Who cannot join
- Participant's PD diagnosis is unclear or there is a suspicion that the subject has a parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome (e.g. Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body disease) or other neurodegenerative disease that might mimic the symptoms of PD.
- Participant(s) has undergone neurosurgery for the treatment of Parkinson's disease.
- Known hypersensitivity to levodopa, carbidopa or radiopaque material.
- Participant(s) has contraindications to levodopa (e.g. narrow angle glaucoma, malignant melanoma).
- Participant(s) experiencing clinically significant sleep attacks or clinically significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any point during the three months prior to the Screening evaluation as judged by the Principal Investigator.
Trial locations and contacts
38 sites in 9 countries.
38 sites in 9 countries
Spain9 sites
Hospital Clinic de Barcelona /ID# 137689
Barcelona, 08036
Hospital Santa Creu i Sant Pau /ID# 136581
Barcelona, 08041
Hospital Puerta del Mar /ID# 157977
Cadiz, 11009
Hospital Universitario Virgen de las Nieves /ID# 136583
Granada, 18014
Hospital Universitario de Bellvitge /ID# 136579
L'Hospitalet de Llobregat, Barcelona, 08907
CHU Insular-Materno Infantil /ID# 136783
Las Palmas de Gran Canaria, Las Palmas, 35016
Hospital Universitario Ramon y Cajal /ID# 136784
Madrid, 28034
Hospital Universitario Virgen del Rocio /ID# 145624
Seville, 41013
Hospital Universitario y Politecnico La Fe /ID# 136722
Valencia, 46026
United States8 sites
Boca Raton Regional Hospital /ID# 200056
Boca Raton, Florida, 33486
Rush University Medical Center /ID# 168088
Chicago, Illinois, 60612
Parkinson's and Movement /ID# 161596
Fountain Valley, California, 92708
University of Florida Neurolog /ID# 168699
Jacksonville, Florida, 32209
St. Luke's Health System /ID# 168706
Kansas City, Missouri, 64111
Parkinson's Disease Treatment Center of Southwest Florida /ID# 168085
Port Charlotte, Florida, 33980
Central Texas Neurology Consul /ID# 168087
Round Rock, Texas, 78681
Inland Northwest Research /ID# 200113
Spokane, Washington, 99202-1342
Italy7 sites
A.O. Univ. Ospedali Riuniti /ID# 135964
Ancona, The Marches, 60126
Ospedale Bellaria.Azienda USL IRCCS.Istituto delle Scienze Neurologiche di Bolog /ID# 136789
Bologna, 40139
A.O.U. Ospedali Riuniti di Fog /ID# 136792
Foggia, 71100
A.O.U. Policlinico G. Martino /ID# 136790
Messina, 98125
Ospedale S.Maria della Miseri /ID# 160609
Perugia, 06132
Azienda Sanitaria Locale di /ID# 160608
Ponderano,biella, 13875
Azienda Policlinico Umberto I /ID# 201223
Roma, 00161
Australia4 sites
Royal Adelaide Hospital /ID# 136577
Adelaide, South Australia, 5000
Royal Melbourne Hospital /ID# 136780
Parkville, Victoria, 3050
Goulburn Valley Hospital /ID# 164202
Shepparton, Victoria, 3630
Westmead Hospital /ID# 136575
Westmead, New South Wales, 2145
Canada3 sites
University of Alberta /ID# 136586
Edmonton, Alberta, T6G 2X8
The Ottawa Hospital /ID# 139341
Ottawa, Ontario, K1H 8L6
Toronto Western Hospital /ID# 136585
Toronto, Ontario, M5T 2S8
South Korea3 sites
Severance Hospital /ID# 163019
Seoul, Seoul Teugbyeolsi, 03722
Seoul National University Hospital /ID# 162990
Seoul, 03080
Asan Medical Center /ID# 163018
Seoul, 05505
Greece2 sites
251 Airforce General Hospital /ID# 160594
Athens, Attica, 11525
Mediterraneo Hospital /ID# 208042
Glyfada, 16675
About this study
Official title: An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.
Read the detailed description
The study will consist of 3 sequential parts:
Part 1: Screening period. The screening period will consist of 3 visits, Visit 1 (V1), Visit 2 ([V2] [optional]) and the Randomization Visit (V3) in which the participant will be assessed to determine eligibility. The duration of the Screening Period can be between 30 to 67 days to accommodate the required procedures, training and collection of diaries, and to allow for stabilization of anti-PD medications and medications to treat NMS. All anti-PD medications and medications to treat NMS are required to be stable for a minimum of 30 days prior to randomization.
Part 2: Treatment period. Those participants randomized to OMT at the end of V3 will remain on their current optimized regimen. The day after randomization will be considered Day 1 of their treatment period and participants will have study visits at the end of Weeks 2, 6, 12, and 26. All participants randomized to the LCIG group should have all anti-PD medications, with the exception of levodopa formulations, tapered off within 14 days after randomization. Optional nasojujunal (NJ) and/or percutaneous endoscopic gastrostomy with a jejunal tube (PEG-J) placement will then occur. After that, the participant may begin initiation and titration of LCIG infusion to be adjusted to obtain the optimal clinical response. The day of initial NJ or PEG-J placement will be considered Day 1 for participants in the LCIG group. Study visits happen at the end of Weeks 2, 6, 12, and 26.
Part 3: Extension/Transition Period. Eligible participants who complete the 26 week study may continue into the Extension Period of the study. Participants in the LCIG arm will have study drug dispensation every 4 weeks and will have study visits every 6 months. Participants from the OMT arm will undergo the NJ (optional) and PEG-J procedures, titration, plus have visits at 2 weeks, 6 weeks, 3 months and 6 months post NJ or PEG-J. Participants will then continue to receive study drug every 4 weeks and will have study visits every 6 months until Duodopa is commercially available. Transition to a Post-Trial Access protocol will be possible if Duodopa does not become commercially available in a location.
- Conditions
- Advanced Parkinson's Disease
- Being tested
- Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
- Keywords
- levodopa-carbidopa intestinal gel, levodopa, carbidopa, Advanced Parkinson's Disease, Non-Motor Symptom Scale NMSS, Parkinson's Disease Sleep Scale PDSS-2, efficacy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Optimized Medical TreatmentDrug
Oral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications.
Levodopa-Carbidopa Intestinal GelDrug
Also called ABT-SLV187, Duodopa, LCIG
Nasojejunal (NJ) tubeDevice
optional prior to PEG-J placement
Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tubeDevice
| Study group | Role | What they receive |
|---|---|---|
| Optimized Medical Treatment (OMT) | Active comparator | Participants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.
Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG. Receives: Drug: Optimized Medical Treatment; Drug: Levodopa-Carbidopa Intestinal Gel; Device: Nasojejunal (NJ) tube; Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube |
| Levodopa-Carbidopa Intestinal Gel (LCIG) | Experimental | Participants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.
The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day.
Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG. Receives: Drug: Levodopa-Carbidopa Intestinal Gel; Device: Nasojejunal (NJ) tube; Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Week 26 in the NMSS Total Score
The NMSS consists of 30 questions in 9 domains (cardiovascular/falls, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, GI tract, urinary, sexual function, miscellaneous). Score of each question is calculated by multiplying severity*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Total score is the sum of 9 domains, and ranges from 0 to 360, with a lower value indicating a more desirable outcome. Repeated-measure analysis.
Measured: Baseline, Week 26
Change From Baseline to Week 26 in the Modified PDSS-2 Total Score
The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.
Measured: Baseline, Week 26
Secondary outcomes (10)
Change From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score
The PDQ-8 is a disease-specific instrument designed to measure aspects of health relevant to PD. Eight questions including the mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort are assessed on a 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Summary index score is the sum of each question divided by 32 and multiplied by 100. Scores range from 0 to 100 with lower values desirable.
Measured: Baseline, Week 26
Clinical Global Impression of Change (CGI-C) Final Score
CGI-C score is a clinician's impression of a subject's change in status on a 7-point scale (1 = very much improved, 2 = much improved, 3 = minimally Improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse). Scores range from 1 to 7, with lower score desirable.
Measured: End of Treatment Period (up to Week 26)
Change From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score
UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part II scores range from 0 to 52 with lower value desirable.
Measured: Baseline, Week 26
Change From Baseline to Week 26 in the NMSS Domain Scores
The NMSS consists of 30 questions in 9 domains. Score of each question is calculated by multiplying severity*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Cardiovascular/falls scores range from 0 - 24 with lower value desirable. Sleep/fatigue scores range from 0 - 48 with lower value desirable. Mood/cognition scores range from 0 - 72 with lower value desirable. Perceptual problems/hallucinations scores range from 0 - 36 with lower value desirable. Attention/memory scores range from 0 - 36 with lower value desirable. Gastrointestinal tract scores range from 0 - 36 with lower value desirable. Urinary scores range from 0 - 36 with lower value desirable. Sexual function scores range from 0 - 24 with lower value desirable. Miscellaneous scores range from 0 - 48 with lower value desirable. Repeated-measure analysis.
Measured: Baseline, Week 26
Change From Baseline to Week 26 in the Modified PDSS-2 Domain Scores
The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.
Measured: Baseline, Week 26
Change From Baseline at Week 26 in UPDRS Parts I, III, and IV Score
UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part I is the sum of Questions 1 - 4; scores range from 0 to 16 with lower value desirable. Part III is the sum of Questions 18 - 31 (Questions 20 - 26 apply to multiple body parts, resulting in 27 answers total); scores range from 0 to 108 with lower value desirable. Part IV is the sum of Questions 32 - 42; scores range from 0 to 23 with lower value desirable.
Measured: Baseline, Week 26
Change From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score
PAS is a 12-item scale developed specifically to measure severity in anxiety in Parkinson's disease for the following items: Feeling anxious or nervous; Feeling tense or stressed; Being unable to relax; Excessive worrying about everyday matters; Fear of something bad, or even the worst, happening; Panic or intense fear; Shortness of breath; Heart palpitations or heart beating fast; Fear of losing control; Social situations; Public settings; Specific objects or situations. Severity for each item is rated as: 0, Never; 1 Rarely; 2, Sometimes; 3, Often; 4, Nearly always. Total score is the sum of the12 item scores, with a range of 0 to 48; a lower value is desirable.
Measured: Baseline, Week 26
Change From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score
The GDS-15 is a short, self-report reliable and valid screening instrument for depression in the elderly of 15 yes/no questions: 1) Satisfied with life 2) Dropped many activities and interests 3) Life is empty 4) Often get bored 5) In good spirits most of the time 6) Afraid that something bad is going to happen 7) Feel happy most of the time 8) Often feel helpless 9) Prefer to stay at home, rather than going out and doing things 10) Feel that have more problems with memory than most 11) Think it is wonderful to be alive now 12) Feel worthless 13) Feel full of energy 14) Situation is hopeless 15) Most subjects are better off. Answers of 'yes' to questions 2, 3, 4, 6, 8, 9, 10, 12, 14, 15 are scored 1 point. Answers of 'no' to questions 1, 5, 7, 11, 13 are scored
1 point. The 15 items are summed and scores range from 0 - 15 with lower value desirable.
Measured: Baseline, Week 26
Change From Baseline at Week 26 in King's PD Pain Scale (KPPS) Score
The KPPS score is a clinical PD-specific pain scale of 14 items addressing the following 7 domains: musculoskeletal pain, chronic pain, fluctuation-related pain, nocturnal pain, orofacial pain, neuropathic pain, radicular pain. Each domain item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 - 12 (with lower value desirable), the sum of the 14 items gives the total score with a range from 0 to 168 with lower value desirable.
Measured: Baseline, Week 26
Patient Global Impression of Change (PGIC) Final Score
The PGIC is a 7-point response scale. The participant was asked by the Investigator or qualified designee to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. PGIC score ranges from 1 to 7 with lower score desirable.
Measured: End of Treatment Period (up to Week 26)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2015 (estimated)
- Study start26 Oct 2015
- Primary completion14 May 2020
- Study completion18 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Advanced Parkinson's DiseaseStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 89 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AbbVie Inc., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02549092
- Sponsor's protocol ID
- M12-927
- Other IDs
- 2014-004865-26, 2014
- Status last verified
- Nov 2023
- First submitted
- 11 Sep 2015
- Last updated
- 28 Nov 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study
- ClinicalTrials.gov ID
- NCT02549092
- Acronym / sponsor ID
- M12-927
- Conditions
- Advanced Parkinson's Disease
- Keywords
- levodopa-carbidopa intestinal gel, levodopa, carbidopa, Advanced Parkinson's Disease, Non-Motor Symptom Scale NMSS, Parkinson's Disease Sleep Scale PDSS-2, efficacy
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 89 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 26 Oct 2015 (actual)
- Primary completion
- 14 May 2020 (actual)
- Study completion
- 18 Nov 2022 (actual)
- First posted
- 15 Sep 2015 (estimated)
- Results
- Posted 3 Jun 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.
Detailed description
The study will consist of 3 sequential parts:
Part 1: Screening period. The screening period will consist of 3 visits, Visit 1 (V1), Visit 2 ([V2] [optional]) and the Randomization Visit (V3) in which the participant will be assessed to determine eligibility. The duration of the Screening Period can be between 30 to 67 days to accommodate the required procedures, training and collection of diaries, and to allow for stabilization of anti-PD medications and medications to treat NMS. All anti-PD medications and medications to treat NMS are required to be stable for a minimum of 30 days prior to randomization.
Part 2: Treatment period. Those participants randomized to OMT at the end of V3 will remain on their current optimized regimen. The day after randomization will be considered Day 1 of their treatment period and participants will have study visits at the end of Weeks 2, 6, 12, and 26. All participants randomized to the LCIG group should have all anti-PD medications, with the exception of levodopa formulations, tapered off within 14 days after randomization. Optional nasojujunal (NJ) and/or percutaneous endoscopic gastrostomy with a jejunal tube (PEG-J) placement will then occur. After that, the participant may begin initiation and titration of LCIG infusion to be adjusted to obtain the optimal clinical response. The day of initial NJ or PEG-J placement will be considered Day 1 for participants in the LCIG group. Study visits happen at the end of Weeks 2, 6, 12, and 26.
Part 3: Extension/Transition Period. Eligible participants who complete the 26 week study may continue into the Extension Period of the study. Participants in the LCIG arm will have study drug dispensation every 4 weeks and will have study visits every 6 months. Participants from the OMT arm will undergo the NJ (optional) and PEG-J procedures, titration, plus have visits at 2 weeks, 6 weeks, 3 months and 6 months post NJ or PEG-J. Participants will then continue to receive study drug every 4 weeks and will have study visits every 6 months until Duodopa is commercially available. Transition to a Post-Trial Access protocol will be possible if Duodopa does not become commercially available in a location.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Optimized Medical Treatment (OMT) | Active comparator | Drug: Optimized Medical Treatment, Drug: Levodopa-Carbidopa Intestinal Gel, Device: Nasojejunal (NJ) tube, Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tubeParticipants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated. Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG. |
| Levodopa-Carbidopa Intestinal Gel (LCIG) | Experimental | Drug: Levodopa-Carbidopa Intestinal Gel, Device: Nasojejunal (NJ) tube, Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tubeParticipants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated. The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day. Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG. |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Participant(s) must have a diagnosis of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria.
- Participant(s) demonstrates persistent motor fluctuations in spite of individually optimized treatment.
- The participant's Parkinson's disease is levodopa-responsive.
- Participant(s) has had optimized treatment with available anti-PD medication and their motor symptoms are judged inadequately controlled on this optimized treatment. Optimized treatment is defined as the maximum therapeutic effect obtained with pharmacological antiparkinsonian therapies when no further improvement is expected regardless of any additional manipulations of levodopa and/or other antiparkinsonian medication. This will be based on the Investigator's clinical judgment.
- Male or female participant(s) must be at least 30 years of age.
Key exclusion criteria (5 listed)
- Participant's PD diagnosis is unclear or there is a suspicion that the subject has a parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome (e.g. Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body disease) or other neurodegenerative disease that might mimic the symptoms of PD.
- Participant(s) has undergone neurosurgery for the treatment of Parkinson's disease.
- Known hypersensitivity to levodopa, carbidopa or radiopaque material.
- Participant(s) has contraindications to levodopa (e.g. narrow angle glaucoma, malignant melanoma).
- Participant(s) experiencing clinically significant sleep attacks or clinically significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any point during the three months prior to the Screening evaluation as judged by the Principal Investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Optimized Medical TreatmentOral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications. | Drug | Optimized Medical Treatment (OMT) |
| Levodopa-Carbidopa Intestinal GelAlso: ABT-SLV187, Duodopa, LCIG | Drug | Levodopa-Carbidopa Intestinal Gel (LCIG), Optimized Medical Treatment (OMT) |
| Nasojejunal (NJ) tubeoptional prior to PEG-J placement | Device | Levodopa-Carbidopa Intestinal Gel (LCIG), Optimized Medical Treatment (OMT) |
| Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube | Device | Levodopa-Carbidopa Intestinal Gel (LCIG), Optimized Medical Treatment (OMT) |
Primary outcome
Change From Baseline to Week 26 in the NMSS Total Score
Time frame: Baseline, Week 26
The NMSS consists of 30 questions in 9 domains (cardiovascular/falls, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, GI tract, urinary, sexual function, miscellaneous). Score of each question is calculated by multiplying severity*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Total score is the sum of 9 domains, and ranges from 0 to 360, with a lower value indicating a more desirable outcome. Repeated-measure analysis.
Change From Baseline to Week 26 in the Modified PDSS-2 Total Score
Time frame: Baseline, Week 26
The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.
10 secondary outcomes
Change From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score
Time frame: Baseline, Week 26
Clinical Global Impression of Change (CGI-C) Final Score
Time frame: End of Treatment Period (up to Week 26)
Change From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in the NMSS Domain Scores
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in the Modified PDSS-2 Domain Scores
Time frame: Baseline, Week 26
Change From Baseline at Week 26 in UPDRS Parts I, III, and IV Score
Time frame: Baseline, Week 26
Change From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score
Time frame: Baseline, Week 26
Change From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score
Time frame: Baseline, Week 26
Change From Baseline at Week 26 in King's PD Pain Scale (KPPS) Score
Time frame: Baseline, Week 26
Patient Global Impression of Change (PGIC) Final Score
Time frame: End of Treatment Period (up to Week 26)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Related trials for Advanced Parkinson's Disease
Not yet recruiting
Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.
Parkinson Disease
Not yet recruitingObservational study
Longitudinal Observation of Neurodegeneration in Parkinson's Disease Using Molecular Imaging and Blood Biomarkers
Idiopathic Parkinson Disease
RecruitingPhase 2
Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS
Parkinson's Disease, Deep Brain Stimulation
Not yet recruitingPhase 1
A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS
PARKINSON DISEASE (Disorder), Cell Therapy
Active, not recruiting
Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes.
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AbbVie Inc. study director
AbbVie
38 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel and Nasojejunal (NJ) tube in people with Advanced Parkinson's Disease, run by AbbVie at 38 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 38 sites in Spain, United States, Italy, Australia, Canada and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Jun 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Week 26 in the NMSS Total Score (time frame: Baseline, Week 26). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2023.